CA9 and neoplasm: Another avenue for the use of CAIX inhibition may be as a combination therapy with antiangiogenic drugs; this could produce additive results, since immunohistochemical data show that CAIX is part of a resistance mechanism that enables tumours to adapt to the increased hypoxia induced by bevacizumab treatment [80].